Articles with keyword immunotherapy

• IMMUNOTHERAPY

  N.M. Volkov

  cancer immunotherapy, effectiveness, toxicity, hyperprogression, predictive biomarkers.

• CANCER IMMUNOTHERAPY

  N.M. Volkov

  cancer immunotherapy, immune check-point inhibitors, chimeric antigen receptor, clinical trials.

• Immunotherapy Resistance – Finding Solutions

  M.Yu. Fedyanin

  cancer, chemotherapy, immunotherapy, resistance.

• Cell-based anticancer immunotherapy methods

  N.M. Volkov

  сell-based immunotherapy, adoptive therapy, dendritic cell, vaccine, T-lymphocyte, natural killer, cancer

• A history of cancer immunotherapy

  V.M. Moiseyenko, N.M. Volkov

  anticancer immunity, cancer immunotherapy, history, vaccines, cytokines, adoptive therapy, antibody, immune check-point inhibitor

• History of immunotherapy of malignant tumors

  M.M. Kramchaninov, V.M. Moiseenko

  cancer, solid tumors, antitumour drugs, immunotherapy, monoclonal antibodies, checkpoint inhibitors

• PROSPECTS FOR IMMUNOTHERAPY OF VIRUS-ASSOCIATED TUMORS

  I.V. Samoilenko, Ya.I. Zhulikov, L.V. Demidov

  virus-associated malignancies, immunotherapy, CAR-T, engineered TCR, anti-PD1.

• Immunotherapy: Neoadjuvant and/or adjuvant? Literature review

  N.A. Falaleeva, E.A. Bykova, L.Yu. Grivtsova, A.S. Belokhvostova, A.А. Danilenko, I.S. Pimonova, P.V. Shegai, S.A. Ivanov, A.D. Kaprin

  Neoadjuvant immunotherapy, immune checkpoint inhibitors, breast cancer, colorectal cancer, non-small cell lung cancer, nonspecific immunotropic therapy.

• FUTURE OF SYSTEMIC THERAPY IN ONCOUROLOGY: TARGETED AND IMMUNOTHERAPY

  F.V. Moiseenko

  immunotherapy, targeted therapy, checkpoint inhibitors, urothelial cancer, renal cell cancer.

• Immunotherapy is based on cytokines (IL-1, IL-2, FNO, CSF, IFN)

  V.A. Chubenko

  immune system, cytokines, interleukins, interferons, colony stimulating agents, microenvironment, strategies of the immunotherapy

• Biomarkers predicting the effect of immunotherapy: what you need to know in practice?

  A.M. Konstantinova

  immunotherapy, CTLA-4, PD-1, PD-L1, microsatellite instability, mutation burden, tumor-infiltrating lymphocytes, biomarkers, efficacy.

• Prospects for the use of small interfering RNAs as inhibitors of immune checkpoints for immunotherapy in oncology

  A.A. Bogdanov, V.V. Vysochinskaya, A.A. Kornev, A.K. Emelyanov, An.A. Bogdanov, V.M. Moiseyenko

  immunotherapy, adaptive cell therapy, RNA interference, targeted therapy, immune checkpoint inhibitors.

• The emerging field of checkpoint inhibitors

  V.A. Chubenko

  immunotherapy, adverse events, predictive markers.

• What has changed in clinical oncology practice In 2019?

  M.Y. Fedyanin

  cancer, chemotherapy, immunotherapy, targeted therapy.

• Microbiome as a therapeutic target

  F.V. Moiseenko

  drug therapy, cancer, microbiome, immunotherapy.

• Microbiome and its role in oncology

  F.V. Moiseenko, S.V. Ugai, N.M. Volkov

  drug therapy, cancer, microbiome, immunotherapy.

• 2018 NOBEL PRIZE IN PHYSIOLOGY OR MEDICINE

  F.V. Moiseenko, V.M. Moiseyenko

  cancer, treatment, immunotherapy, checkpoint inhibitors.

• What should we consider besides immune checkpoint drugs on the way to improvement of the efficacy?

  F.V. Moiseenko

  cancer, malignant tumors, immunotherapy, metabolism, microbiom.

• 2016: advances in medical oncology

  V.A. Chubenko

  immunotherapy, target therapy, overall survival, treatment guidelines

• Immunologic aspects of tumor biology

  N.M. Volkov

  malignant tumors, immune surveillance theory, immunoediting, immunotherapy

• The role of stereotaxic body radiotherapy (sbrt) in the treatment of patients with distant metastases

  N.V. Dengina

  oligometastases, radiation therapy, SBRT, abscopal effect, immunotherapy

• Colorect al molecular subtypes – progress or deadlock ?

  M.Yu. Fedyanin, E.O. Ignatova, А.А. Tryakin

  colorectal cancer, molecular subtypes, immunotherapy, targeted therapy.

• Immune checkpoint inhibitors in the treatment of cervical cancer: literature review

  O.A. Pardabekova

  cervical cancer, immunotherapy, immune checkpoint inhibitors, pd-1,

• MEDICAL TREATMENT OF TUMORS: WHAT NEED TO KNOW A PRAC TICAL ONCOLOGIST

  V.A. Chubenko

  chemotherapy, immunotherapy, target therapy, overall survival, treatment guidelines.

• Myeloid-derived suppressor cells: origin, phenotype, functions, mechanisms of interaction with immune cells during tumor growth

  T.N. Zabotina, I.O. Panchuk, D.V. Tabakov, E.N. Zakharova

  myeloid suppressor cells, immunosuppression, oncology, immunotherapy, antitumor immunity.

• Palliative radiation therapy – is there a place for this method in modern practical oncology

  T.M. Sharabura, T.N. Bochkareva

  palliative radiation therapy, stereotactic ablative radiotherapy, oligometastatic disease, immunotherapy

• New and promising immune oncology drugs combinations

  N.М. Volkov

  malignant tumors, cancer immunotherapy, immune check-point inhibitors, combinations.

• Application of biomedical cell products based on natural killer cells and cytokine-induced killer cells for the treatment of oncological diseases

  A.O. Malasheuskaya, N.G. Antonevich, A.Y. Hancharou

  natural killer cells, cytokine-induced killer cells, biomedical cell product, cancer, immunotherapy.

• Tumor-infiltrating lymphocytes – from theory to real practice

  N.M. Volkov

  immunotherapy, adoptive therapy, T-lymphocyte, tumor-infiltrating lymphocytes, melanoma, malignant tumors.

• Oncologic Surgery in the era of drug therapy

  V.V. Egorenkov

  immunotherapy, adoptive therapy, T-lymphocyte, tumor-infiltrating lymphocytes, melanoma, malignant tumors

• The role of using circulating tumor dna in the treatment of disseminated patients with non-small cell lung cancer

  К.К. Laktionov, А.М. Kazakov, М.G. Gordiev

  circulating tumor DNA, tumor mutation burden, non-small cell lung cancer, immunotherapy.

• 2015 main events in drug therapy

  F.V. Moiseenko

  immunotherapy, program cell death protein inhibitors, targeted therapy, cancer drug therapy

• Percutaneous energy-based tumor ablation: principles, technologies, results

  P.V. Balakhnin, A.S. Shmelev, E.G. Shachinov

  radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation, laser ablation, ultrasound ablation, cancer immunotherapy, interventional radiology

• The most important results of clinical trials for breast cancer systemic therapy in 2021

  S.A. Tjulandin, М.В. Stenina, М.А. Frolova

  breast cancer, immunotherapy, endocrine therapy, chemotherapy, gene expression assay, BRCA1/2-associated breast cancer.

• Fundamental oncology in 2015: a review of the most interesting discoveries

  E.N. Imyanitov

  сancer immunotherapy, fundamental oncology, microsatellite instability, acquired cancer resistance, circulating tumor DNA, cancer hormonotherapy, KRAS mutation

• Urgent issues of drug therapy and possible solutions

  E.V. Karabina

  precision oncology, effectiveness of immunotherapy of malignant tumors, effectiveness of chemotherapy of malignant tumors, recovery of patients with advanced cancer.

• RADIATION ONCOLOGY: NOTA BENE FOR PRAC TICING ONCOLOGISTS

  N.V. Dengina, T.V. Mitin

  radiation oncology, multidisciplinary team, chemoradiotherapy, trimodality treatment, radiotherapy effect evaluation, combination of radiotherapy and immunotherapy.

• Efficacy of immune checkpoints inhibitors in the treatment of solid tumors

  A.A. Rumyantsev, S.A. Tjulandin

  drug therapy, immunotherapy, CTLA-4, PD-1, PD-L1, check-points, programmed cell death protein, nivolumab, pembrolizumab, ipilimumab, atezolizumab, biomarkers, efficacy

• Modern approa hes to the treatment of primary multiple unilateral synchronous lung tumors (literature review)

  I.V. Mosin, S.M. Nuraliev, A.G. Pavlov, V.M. Moiseenko

  Lung cancer, primary multiple synchronous and metachronous lung tumors, classification, diagnosis, staging, stereotactic radiation therapy, targeted therapy, immunotherapy, anatomical segmentectomy, lobectomy, bronchoplastic surgery.